Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.50 |
| ▸ | ATM | Q13315 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ESR1 | P03372 | 2/20 | 0.34 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | PGR | P06401 | 1/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
| ▸ | BCL2 | P10415 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12275774 | 0.77 | ATM (0.41) | PARP1ATMALDH1A1ESR1ESR2 | |
| SCHEMBL5475013 | 0.74 | NPC1 (0.54) | ATMALDH1A1KDM4EESR1CA1 | |
| SCHEMBL13806417 | 0.73 | ATM (0.50) | ATMALDH1A1KDM4ENPC1RAB9A | |
| SCHEMBL1394239 | 0.73 | ATM (0.50) | ATMALDH1A1KDM4ENPC1RAB9A | |
| SCHEMBL2796407 | 0.73 | ATM (0.50) | ATMALDH1A1KDM4ENPC1RAB9A | |
| SCHEMBL25413825 | 0.73 | ATM (0.50) | ATMALDH1A1KDM4ENPC1RAB9A | |
| SCHEMBL8512795 | 0.73 | ATM (0.50) | ATMALDH1A1KDM4ENPC1RAB9A | |
| SCHEMBL7479947 | 0.73 | ATM (0.50) | PARP1ATMALDH1A1KDM4ENPC1 | |
| SCHEMBL1285478 | 0.73 | ATM (0.50) | ATMALDH1A1KDM4ENPC1RAB9A | |
| SCHEMBL4164409 | 0.73 | ATM (0.50) | PARP1ATMALDH1A1KDM4EESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7960548-B2 | Keratinocyte growth factor receptor—tyrosine specific inhibitors for the prevention of cancer metastatis | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2011-06-14 | — | — | US | disclosed |
| EP-1883403-A2 | KERATINOCYTE GROWTH FACTOR RECEPTOR - TYROSINE SPECIFIC INHIBITORS FOR THE PREVENTION OF CANCER METASTATIS | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2008-02-06 | — | — | EP | disclosed |
| US-20070078176-A1 | Keratinocyte growth factor receptor-tyrosine specific inhibitors for the prevention of cancer metastatis | US ARMY, SECRETARY OF THE ARMY | 2007-04-05 | — | — | US | disclosed |
| US-20070032518-A1 | Compounds and methods of use | AMGEN INC. (US) | 2007-02-08 | — | — | US | disclosed |
| WO-2006119148-A2 | KERATINOCYTE GROWTH FACTOR RECEPTOR - TYROSINE SPECIFIC INHIBITORS FOR THE PREVENTION OF CANCER METASTATIS | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2006-11-09 | — | — | WO | disclosed |
| EP-1478645-A2 | QUINOLINONE DERIVATIVES FOR TREATING CELL PROLIFERATION RELATED DISORDERS | Amgen Inc. (US) | 2004-11-24 | — | — | EP | disclosed |
| US-6822097-B1 | THIAZOLE-SUBSTITUTED QUINOLINE DERIVATIVES; ANTICARCINOGENIC AGENTS, ANTISTROKE AGENTS; APOPTOSIS AND CELL PROLIFERATION TREATMENT; NERVOUS SYSTEM DISORDERS | AMGEN, INC. | 2004-11-23 | — | — | US | disclosed |
| WO-2003066630-A2 | QUINOLINONE DERIVATIVES FOR TREATING CELL PROLIFERATION RELATED DISORDERS | AMGEN INC. (US) | 2003-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070078176-A1 | Keratinocyte growth factor receptor-tyrosine specific inhibitors for the prevention of cancer metastatis | FGFR1, FGFR3, MET | PARP1 4580/4885ATM 743/4885ALDH1A1 1697/4885 |
| US-20070032518-A1 | Compounds and methods of use | BAX, BAD, CASP3 | PARP1 490/4885ATM 1868/4885ALDH1A1 282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.